1. Home
  2. SHCO vs SNDX Comparison

SHCO vs SNDX Comparison

Compare SHCO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHCO
  • SNDX
  • Stock Information
  • Founded
  • SHCO 1995
  • SNDX 2005
  • Country
  • SHCO United Kingdom
  • SNDX United States
  • Employees
  • SHCO N/A
  • SNDX N/A
  • Industry
  • SHCO Hotels/Resorts
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHCO Consumer Discretionary
  • SNDX Health Care
  • Exchange
  • SHCO Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • SHCO 1.0B
  • SNDX 1.1B
  • IPO Year
  • SHCO 2021
  • SNDX 2016
  • Fundamental
  • Price
  • SHCO $8.85
  • SNDX $16.25
  • Analyst Decision
  • SHCO Strong Buy
  • SNDX Strong Buy
  • Analyst Count
  • SHCO 1
  • SNDX 10
  • Target Price
  • SHCO $9.00
  • SNDX $38.40
  • AVG Volume (30 Days)
  • SHCO 2.4M
  • SNDX 2.2M
  • Earning Date
  • SHCO 08-08-2025
  • SNDX 11-04-2025
  • Dividend Yield
  • SHCO N/A
  • SNDX N/A
  • EPS Growth
  • SHCO N/A
  • SNDX N/A
  • EPS
  • SHCO N/A
  • SNDX N/A
  • Revenue
  • SHCO $1,251,591,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • SHCO $10.81
  • SNDX $585.73
  • Revenue Next Year
  • SHCO $7.12
  • SNDX $94.17
  • P/E Ratio
  • SHCO N/A
  • SNDX N/A
  • Revenue Growth
  • SHCO 9.00
  • SNDX 2126.66
  • 52 Week Low
  • SHCO $4.60
  • SNDX $8.58
  • 52 Week High
  • SHCO $8.92
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • SHCO 75.30
  • SNDX 63.24
  • Support Level
  • SHCO $8.81
  • SNDX $15.59
  • Resistance Level
  • SHCO $8.88
  • SNDX $16.65
  • Average True Range (ATR)
  • SHCO 0.03
  • SNDX 0.78
  • MACD
  • SHCO -0.06
  • SNDX -0.20
  • Stochastic Oscillator
  • SHCO 50.00
  • SNDX 51.26

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: